dm+d

Unassigned

New Medicines

Duchenne muscular dystrophy

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Feb 21No longer in Pfizer pipeline [5], assume discontinued.
Aug 18Pfizer has halted two studies involving domagrozumab in Duchenne Muscular Dystrophy, including NCT02907619, due to lack of efficacy [4].

Category

An anti-myostatin monoclonal antibody.
DMD is a genetic disorder characterised by progressive muscle degeneration and weakness. The disease affects around one in 3,500 male births worldwide, but as yet there are no treatment options for patients [1].
Duchenne muscular dystrophy
Intravenous